Thursday, July 25, 2024

Top 5 This Week

An Expansion Bid to Completely Redefine Our Idea of Nutritional Bioavailability

Pressure BioSciences, Inc, (PBIO) a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products, has officially announced that its wholly-owned Health & Wellness direct-to-consumer subsidiary, Uncle Bud’s is set to expand product portfolio in 2024. According to certain reports, the stated new products will join Uncle Bud’s recently-formed “Premium Collection” line, which offers state-of-the-art nanoemulsified products. More on the company’s Premium Collection line would reveal how it is specifically designed to provide the best possible innovation in performance and quality for a new generation of diverse nanoemulsion products. Processed with PBIO’s multi-patented UltraShear Technology™ platform, the products falling into this segment are crafted from 100% natural, organic, preservative-free clean ingredients, and at the same time, they are also completely GMO-free, Before we dig any further into this development, though, we must acknowledge how many health and wellness products use oil-soluble active compounds, and because of their inherent poor solubility, these products generally tend to provide customers with poor to mediocre onset, absorption, and bioavailability. This means that the consumer benefits from only a small amount of the active ingredient purchased and used. Fortunately, Uncle Bud’s Premium Collection addresses that through UltraShear technology, which improves upon the current reality in many important performance characteristics, ranging from speed of first effects and total payload delivery to product bioavailability, safety, and overall stability.

“These UltraShear-processed Premium Collection products will be released systematically throughout 2024, and are expected to dramatically strengthen and diversify our sales growth, both in Uncle Bud’s and for PBIO overall. We are rapidly engaging, earning, and securing early interest and commitments. We have already started initial development projects with several of the top winery, cosmetics, and nutraceutical companies in the world. We expect these new relationships to evolve into strong revenue-generating customers in 2024 and beyond,” said Ric Schumacher, President and CEO of Pressure BioSciences.

Now, moving on what areas Uncle Bud’s will likely target under its bid for expansion, the answer begins from nootropics. The company’s nootropics line will try and enhance for users their cognitive function, memory, focus, recall power, creativity, problem-solving, and motivation etc. Next up, Uncle Bud’s will bring a set of immunity boosters and sleep-inducing products. In the former’s case, the core idea is unsurprisingly rooted in the strengthening of body’s ability to fight off pathogens, whereas the latter products will come with an aim to promote rest, relaxation, and help the individual’s ability to fall asleep. Markedly enough, the company will also have in place a plan to introduce skincare products. These products, on their part, can be expected to generate anti-aging effects, achieve wrinkle reduction, along with better moisturization, and penetration. Almost like an extension of the same, Uncle Bud’s will also deliver products preaching a better brand of female hygiene. Hence, the stuff released under this category should enable consumers to access improved moisturization, absorption, stability, efficacy, and relief. Another detail worth a mention talks to the company’s pledge to offer new sexual wellness products, products that will, in essence, scale up bioavailability, enhance sensory experience, and accelerate onset of effects.

“Each new market sector that Uncle Bud’s will be addressing with its expanding Premium Collection is larger by multiples than the market for our current CBD products. We anticipate our UltraShear platform will open up revenue generation in each of these new sectors that will dwarf our early efforts focused on CBD, which we still believe will be a strong revenue-generating product line for PBIO in 2024,” said John Hollister, Director of Sales and Marketing at Pressure BioSciences.